Deerfield Private Design Fund III, L.P.'s Net Worth

$163 Million

Who is Deerfield Private Design Fund III, L.P.?

Deerfield Private Design Fund III, L.P. has an estimated net worth of $163 Million. This is based on reported shares across multiple companies, which include Fractyl Health, Inc., RHYTHM PHARMACEUTICALS, INC., XERIS PHARMACEUTICALS INC, REGENXBIO Inc., Editas Medicine, Inc., Shockwave Medical, Inc., AERIE PHARMACEUTICALS INC, ARVINAS INC., Neos Therapeutics, Inc., Avalanche Biotechnologies, Inc., GRAYBUG VISION, INC., Acutus Medical, Inc., Larimar Therapeutics, Inc., Syros Pharmaceuticals, Inc., CytomX Therapeutics, Inc., PROTEON THERAPEUTICS INC, AveXis, Inc., SteadyMed Ltd., aTYR PHARMA INC, LUMOS PHARMA, INC., ALIMERA SCIENCES INC, Homology Medicines, Inc., Oncorus, Inc., Audentes Therapeutics, Inc., and ARS Pharmaceuticals, Inc..

SEC CIK

Deerfield Private Design Fund III, L.P.'s CIK is 0001603333

Past Insider Trading and Trends

2015 was Deerfield Private Design Fund III, L.P.'s most active year for acquiring shares with 65 total transactions. Deerfield Private Design Fund III, L.P.'s most active month to acquire stocks was the month of September. 2022 was Deerfield Private Design Fund III, L.P.'s most active year for disposing of shares, totalling 33 transactions. Deerfield Private Design Fund III, L.P.'s most active month to dispose stocks was the month of November. 2020 saw Deerfield Private Design Fund III, L.P. paying a total of $67,000,000.00 for 12,487,161 shares, this is the most they've acquired in one year. In 2020 Deerfield Private Design Fund III, L.P. cashed out on 59,843,941 shares for a total of $18,052,380.80, their largest year based on trade value.